Axsome launches SYMBRAVO for acute migraine treatment in U.S.

Axsome Therapeutics, Inc.

SYMBRAVO (meloxicam/rizatriptan) now available by prescription for acute migraine with or without aura in adults.
Novel multi-mechanistic approach targeting multiple migraine pathways; rapid pain freedom at 2 hours vs placebo, sustained up to 24 hours.
Axsome launches SYMBRAVO On My Side patient support program including savings card for eligible patients.
SYMBRAVO uses Axsome's patented MoSEIC technology; migraine affects ~40M Americans, 63% not satisfied with current treatments.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.